Kornimate/medical-research-clean huggingface dataset:
effect of ultrasound positioning assisted cheek needle therapy on postoperative recovery quality of patients with radical resection of lung cancer

Conditions: Surgery

Summary: to explore the effect of ultrasound positioning assisted buccal acupuncture on postoperative pain and recovery quality of patients undergoing thoracoscopic radical resection


Eligibility criteria:
inclusion criteria: 1. tracheal intubation under general anesthesia 2. young and middle-aged patients aged 18-65 years 3. bmi: 18.5-28kg /m2 exclusion criteria: 1. head and facial trauma, infection, disease 2. more than 2 kinds of coronary heart disease, hypertension, stroke, diabetes, immune disease and other diseases before surgery
a 6-week study to evaluate the safety and efficacy of methylphenidate hcl erct in 4-5 year old children with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this 6-week study is to determine if the study drug, methylphenidate hydrochloride (hcl) extended-release chewable tablets (erct), is safe, tolerable and effective when compared to a sugar pill or placebo in children 4 to 5 years of age with adhd.

phase 4 double-blind, randomized, parallel group, placebo-controlled study of the efficacy and safety of methylphenidate hydrochloride (hcl) extended release chewable tablets (erct) in 4-5 year old children with attention deficit hyperactivity disorder (adhd)

Eligibility criteria:
inclusion criteria: 1. male or female child 4-5 years of age at screening. 2. signed and dated informed consent provided by the subject's parent/legal and assent of the child (as applicable). 3. meets dsm-5 criteria for adhd based on the k-sads-pl. 4. adhd rs-iv preschool-home version score at screening and baseline \>/= 90th percentile for gender and age in \>/=1 of the following: hyperactive-impulsive subscale, inattentive subscale, or total score. 5. peabody picture vocabulary test 4 (ppvt-4)standard score \>/=70. 6. child global assessment scale (cgas) score \</= 55. 7. participation in a school type program (day care, preschool, kindergarten, transitional kindergarten, or elementary school) for at least \>/=2 half days of the week for at least 3 months and that is anticipated to continue during the study. 8. history of an adequate course of non medication treatment for adhd based on investigator judgment or, where such treatments are not available, the severity of the subject's adhd symptoms are such that medication treatment is deemed necessary by the investigator exclusion criteria: 1. treated with atomoxetine within 30 days prior to the baseline. 2. received any investigational products or devices within 30 days prior to the baseline visit. 3. history of stimulant nonresponse, intolerability or hypersensitivity to any dose of methylphenidate or other stimulant. if a known allergy to d\&c red #30, he/she should not be enrolled in the study. 4. an intelligence quotient (iq) \<70. 5. history of acute or chronic medical or psychiatric condition or cardiac or laboratory abnormality. 6. less than 5th percentile for height or weight at screening. 7. history of recent clinically significant self-harming behaviors.
implementing a paced deep breathing module to decrease preoperative anxiety in gynecological surgery patients

Conditions: Anxiety

Summary: preoperative anxiety is a common occurrence for many patients undergoing all types of surgery. patients with a high level of anxiety before surgery have been shown to have numerous negative outcomes both intra-operatively and post-operatively. many studies have shown that preoperative psychological interventions that aim to reduce anxiety also result in improved post-operative behavioral and clinical recovery. currently, the most common method to treat preoperative anxiety is the administration of a prescription benzodiazepine. however, there is limited clinical evidence that supports the use of sedative premedication, such as with a benzodiazepine, before surgery. complementary integrative medical therapies including music, massage, guided imagery, and deep breathing have been proposed to minimize stress and pain in surgical patients. these therapies are thought to be effective by evoking the relaxation response through stimulation of the parasympathetic nervous system and engagement of the patient in the healing process. relaxation and deep breathing, particularly, have been shown to reduce pain, anxiety, and "tension-anxiety" in hospitalized patients. based on this evidence, a guided paced deep breathing module has been proposed to reduce preoperative anxiety in patients undergoing gynecological surgery at mayo clinic rochester methodist hospital. in this study, patients' anxiety will be assessed pre-intervention on a 0-10 numeric rating scale, as well as post-intervention and a paired t-test will be used to assess effectiveness. additionally, qualitative questions will be administered via a questionnaire post-intervention to gain more insight on the effectiveness of the intervention. the feasibility of the intervention in the busy preoperative setting will be evaluated by assessing how many times a patient is interrupted while participating in the paced deep breathing module. if this module is found to be effective in reducing patients' anxiety, it will be implemented into practice so that every patient undergoing gynecological surgery, at the institution, will be offered the module preoperatively.


Eligibility criteria:
inclusion criteria: * women * aged 18 years or older * undergoing gynecological surgery at rochester methodist hospital * roomed in pre-operative area on eisenberg 1-4 * english-speaking * able to complete pre- and post-intervention questionnaires * able to read and understand informed consent form exclusion criteria: * non-english speaking women * first-case of the day gynecological surgery patients
a study to investigate gw274150 or prednisolone in rheumatoid arthritis taken repeatedly for 28 days.

Conditions: Arthritis, Rheumatoid

Summary: this is an exploratory study to examine the effect of inos inhibition in rheumatoid arthritis patients. the study involves 28 days repeat dosing with gw274150 (dose determined by the results from a previous study), prednisolone (7.5mg) or placebo.


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis according to the revised 1987 criteria of the american college of rheumatology * female subjects who are not capable of becoming pregnant * active disease defined as disease activity score (das) 28 = 4.0 and at least one metacarpal-phalangeal finger (mcp) joint with either detectable vascularity or thickness * stable doses of disease modifying anti-rheumatic drugs (dmards), (which can include but is not restricted to methotrexate, sulphasalazine and hydroxychloroquine in any combination) for 8 weeks prior to enrollment * patients receiving methotrexate must be on stable folate supplements * must have been on stable doses for 2 weeks prior to screening if using cox inhibitors * signed consent form * the patient is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions exclusion criteria: * the subject is using, or has used, oral glucocorticoids within 8 weeks of enrollment * the subject is currently receiving anti-rheumatic biological therapy (e.g. infliximab, adalimumab, etanercept or anakinra) * the subject received their final dose of infliximab or adalimumab within 3 months of enrollment * the subject received their final dose of etanercept or anakinra within 1 month of enrollment * the subject has received another investigational drug within 30 days * the subject drinks more than 28 units (male) or 21 units (female) of alcohol in a week * history of liver or renal disease in the 6 months prior to screening * the subject has a history of drug or other allergy * subject is positive for hepatitis b and c or hiv virus * the subject has positive pregnancy test * the subject has positive test for drugs of abuse

Keywords: inos exhaled no rheumatoid arthritis
evaluation of the optimal technique for determination of renal function of critically ill patients

Conditions: Renal Function; Critical Illness

Summary: the purpose of this study is to evaluate the optimal technique for determination of the renal function of critically ill patients.


Eligibility criteria:
inclusion criteria: * over 18 years old * intensive care patient * given informed consent * arterial infusion * a bladder catheter exclusion criteria: * diurese \< 400 ml/d
vitro-trial. b vitamins and the secondary prevention of venous thrombosis

Conditions: Deep-Vein Thrombosis; Pulmonary Embolism

Summary: the vitro (vitamins and thrombosis) study investigated the effect of homocysteine lowering by daily supplementation of b-vitamins on the risk reduction of deep-vein thrombosis and pulmonary embolism. patients between 20 to 80 years old with a first objectively confirmed proximal deep-vein thrombosis or pulmonary embolism in the absence of major risk factors and a homocysteine concentration above the 75th percentile of a reference group were asked to participate (hyperhomocysteinemic group). a similar study was conducted in a random sample of patients with a homocysteine below the 75th percentile of the reference group (normohomocysteinemic group). after informed consent patients were randomized to daily multivitamin supplementation (5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin) or placebo and were followed for 2.5 years. end-points were objectively diagnosed recurrent deep-vein thrombosis or pulmonary embolism.


Eligibility criteria:
inclusion criteria: * objectively confirmed proximal deep-vein thrombosis or pulmonary embolism * idiopathic thrombosis (i.e. absence of major risk factors (major surgery, known malignant disease, pregnancy and puerperium or immobility for more than three weeks) * age between 20 to 80 years exclusion criteria: * obligatory use of vitamin b

Keywords: venous thrombosis deep-vein thrombosis pulmonary embolism homocysteine b-vitamins folate vitamin b12 vitamin b6
jinfukang oral liquid combined with chemotherapy for treating driver gene-negative advanced nsclc

Conditions: Non Small Cell Lung Cancer

Summary: this is a prospective, randomized, multicenter real-world study, which aims to investigate the efficacy and safety of jinfukang oral liquid combined with chemotherapy as first-line treatment regimen for patients with driver-negative advanced nsclc. 328 patients with unresectable stage iiib-iv nsclc and qi-yin deficiency will be divided into experimental (n=164) and control groups (n=164) according to the stratified blocked randomization.


Eligibility criteria:
inclusion criteria: 1. 18-80 years of age; 2. patients with stage ⅲb-iv nsclc are diagnosed by histopathology and cytology; 3. patients' tumor tissues are unresectable as assessed by the investigator; 4. have measurable disease based on recist 1.1; 5. driver gene (egfr/alk/ros1) is negative; 6. patients who are receiving first-line platinum-doublet chemotherapy with remaining no fewer than 4 therapeutic cycles; 7. patients in chemotherapy who combined with other systemic therapy (including but not limited to immune checkpoint inhibitors and anti-vascular targeted drugs) are not suitable, but with radiotherapy can be permitted; 8. during chemotherapy cycles, patients who take prior treatment with anticancer chinese medicine less than 4 weeks can be enrolled after stopping medication. if administration time is longer than 4 weeks, at least 4 weeks washout period should be performed; 9. patients are diagnosed with qi-yin deficiency by the syndrome differentiation of traditional chinese medicine; 10. the expected survival time ≥3 months; 11. the subjects volunteer to sign the informed consent. exclusion criteria: 1. allergy or hypersensitivity to ingredients of the study treatment formulation; 2. pregnant or lactating women; 3. patients with multiple brain metastases, multiple bone metastases and liver metastases, which have great influence on survival times； 4. patients are enrolling in other therapeutic trials; 5. the investigator does not consider the participant to be eligible for this study.
cortical neuromodulation in post stroke dysphagia

Conditions: Dysphagia

Summary: the investigators aim is to try to rehabilitate post stroke dysphagia using electrical stimulation of the mylohyoid muscles.

aspiration could have fatal complication especially in post stroke dysphagia. the aim of this study is to improve post stroke dysphagia using electrical stimulation of mylohyoid muscles. the investigators measure swallowing time before and after electrical stimulation, performed one hour per day, 5 consecutive days during paste consistency swallowing

Eligibility criteria:
inclusion criteria: * post stroke dysphagia exclusion criteria: * contraindication to magnetic stimulation, unability to accept the study

Keywords: swallowing stroke aspiration human electrical stimulation post stroke dysphagia
ultrasound-guided transmuscular quadratus lumborum block for elective laparoscopic hand-assisted nephrectomy and robot assisted partiel nephrectomy

Conditions: Postoperative Pain; Ultrasound Guided Transmuscular Quadratus Lumborum Block

Summary: patients with kidney cancer often undergo hand-assisted laparoscopic nephrectomy or robot assisted partiel nephrectomy. the investigators performed a one-year retrospective study. the sudy revealed that 67% of the patients needed substantial amounts of opioids for postoperative pain management (ppm) in recovery despite a multimodal analgesic regime. in a prospective pilot study including ten laparoscopic hand-assisted nephrectomy, with severe postoperative pain the investigators found that bilateral ultrasound-guided (usg) transmuscular quadratus lumborum (tql) block substantially reduced pain and opioid consumption. this study aims to evaluate the effect on ppm of a bilateral usg tql block compared to placebo.


Eligibility criteria:
inclusion criteria: * over 18 years * kidney cancer * have received thorough information, orally and in written * signed the "informed consent" form on participation in the trial exclusion criteria: * inability to cooperate * inability to speak and understand danish both orally and written * allergy to local anaesthetics or opioids * daily intake of opioids * local infection at the site of injection or systemic infection * difficulty visualisation of muscular and fascial structures in ultrasound visualisation necessary to the block administration * known abuse of alcohol or medicine * pregnancy
barre exercise in parkinson's

Conditions: Parkinson Disease

Summary: this study asks if a barre exercise program is a feasible and acceptable form of exercise for individuals with parkinson disease. the study will also evaluate barre's potential effects on motor outcomes, including balance, strength, and functional mobility.

the primary objectives of this study are to: 1) evaluate the feasibility and acceptability of a barre exercise intervention and 2) gather preliminary data regarding the effect of a barre exercise intervention on balance, strength, functional mobility and quality of life in individuals with mild to moderate parkinson disease (pd). individuals with pd (n=15) will be recruited to participate in a pilot barre exercise class led by a certified barre instructor. the intervention will include 24, 45-50 minute group classes (twice weekly for 12 weeks, excluding holidays). pre- and post-intervention data collection will include assessments of balance, lower extremity strength, and functional mobility.

Eligibility criteria:
inclusion criteria: * diagnosed by a neurologist with idiopathic parkinson disease * at least 18 years of age * a score on the hoehn \& yahr (h\&y) scale between i-iii to indicate mild to moderate disease severity * able to provide informed consent * able to walk for 10 continuous minutes without assistance from another person * stable medication regimen for at least one month prior to enrollment exclusion criteria: * any neurological condition other than pd * history of orthopedic or other medical conditions that limit the ability to safely participate in the intervention or * language, visual, or hearing barriers to participation * evidence of dementia (montreal cognitive assessment \< 24) to ensure understanding of the intervention class instructions
cold applications on the pain level of children with sutures

Conditions: Child, Only

Summary: purpose:this research was conducted as an experimental study with pretest and posttest control groups in order to evaluate the effect of post-suture cold applications on the pain level of children with sutures. design and methods: this study is a randomised controlled study. in the study, there were 150 children in the experimental group and 150 children in the control group.

the experimental groups was applied at the 1st, 2nd and 6th hours after the suture application in the cold applications the different practitioners applied in the visual analog scale after and before in the cold applications to the experimental and control groups

Eligibility criteria:
inclusion criteria: * parents who agreed to participate in the study exclusion criteria: * -visually impaired child * mentally retarded child * speech impaired children * without chronic disease

Keywords: cold application child nurse pain suture
clinical tumor anemia registry (tar)

Conditions: Anemia

Summary: the purpose of this registry is to record information of routine treatment of anemia in cancer patients in germany. an overview of the current treatment of anemia in german outpatient centers and hospitals will be provided. primary outcome parameters, e.g. improvement in hemoglobin levels and changes in qol, as well as patient characteristics of different treatments will be analyzed.


Eligibility criteria:
inclusion criteria: * histologically confirmed malignant disease * hemoglobin level \< 11 g/dl (female) or \< 12 g/dl (male) * start of antianemic therapy no more than 7 days prior to informed consent * performance status 0 - 3 (karnofsky-index \>= 40%) * minimum age: 18 years * informed written consent exclusion criteria: * hypersensitivity against antianemic therapies * myelodysplastic syndrome * experimental antianemic therapy

Keywords: anemia cancer hemoglobin quality of life fact-an fact-gp erythropoiesis-stimulating agents (esa) epoetin ferric carboxymaltose blood transfusions
a translational study of bevacizumab in participants with metastatic colorectal cancer

Conditions: Colorectal Neoplasms

Summary: this open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (pfs) in participants with previously untreated metastatic colorectal cancer. the study consists of two phases: phase a treatment: oral capecitabine plus infusional oxaliplatin (xelox) plus bevacizumab, or modified infusional 5-fluorouracil (5-fu), leucovorin (lv) and oxaliplatin (mfolfox6) plus bevacizmab administered until first disease progression. participants will then continue with phase b treatment: infusional 5-fu, lv and irinotecan (folfiri) plus bevacizumab until second disease progression. the anticipated time on study treatment is 4 years.


Eligibility criteria:
inclusion criteria: for resected primary tumor participants, and participants with primary tumor in situ: * previously untreated metastatic colorectal cancer and not a candidate for curative resection * world health organization (who) performance status of 0-1 * life expectancy of greater than or equal to (\>/=) 3 months * eligible for xelox, mfolfox6, folfiri and bevacizumab treatment in accordance with local standards of care and pharmaceutical benefits scheme guidelines additional inclusion criteria for participants with primary tumor in situ: * intact primary tumor of the colon or the rectum not requiring surgical intervention prior to study start * minimal or asymptomatic primary tumor exclusion criteria: resected primary tumor participants, and participants with primary tumor in situ: * previous chemotherapy for metastatic colorectal cancer * previous neoadjuvant or adjuvant chemotherapy less than 6 months prior to study start * radiotherapy within 28 days prior to enrollment or not recovered from a radiotherapy * history of non-colorectal cancer (participants are eligible if disease-free for \>/=5 years and the risk of recurrence is deemed low) * presence of active inflammatory bowel disease * history of gastrointestinal perforations * peritoneal disease * history of significant bleeding event * significant vascular disease * peripheral arterial thrombosis or other thrombotic event within 6 months before study start additional exclusion criteria for participants with primary tumor in situ: * prior endoscopic management of the current tumor * acute diverticulitis * presence of intra-abdominal abscess * active gastroduodenal ulcer
cik in treating patients with bladder cancer

Conditions: Urinary Bladder Neoplasms

Summary: chemotherapy is the main treatment method for patients with bladder cancer. however, relapse remains the major cause of treatment failure.biological therapies such as cik stimulate the immune system and stop tumor cells from growing. a series of studies reported that cytokine-induced killer cells (cik) have a broad anti-tumor spectrum. the investigators suppose that cik will improve the prognosis. combining chemotherapy with biological therapy may kill more tumor cells. in this study, the patients will be treated with cik cells after chemotherapy. the purpose of this study is to evaluate the efficacy of cik for bladder cancer.

about 1500 patients with staging i-iii of bladder cancer, after accepting chemotherapy, will be randomly divided into group a (receive cik treatment) or group b (just regularly follow up), and the randomize ratio will be 1:1. patients in group a will receive 3 cycles of cik cells treatment (every 12 weeks). patients in group b will have no anti-tumor therapy.

Eligibility criteria:
inclusion criteria: * patients histologically confirmed carcinoma in of the bladder with urinary cytology; * patients with staging i-iii of bladder cancer; * patients who had completed chemotherapy; * patients who have a life expectancy of at least 12 weeks; * eastern cooperative oncology group (ecog) performance status was 0-1; * the bone marrow functioned normally (wbc\>4.0×10\^9/l, hb\>120 g/l, platelet(plt)\>100×10\^9/l); * the ecg results were normal, and the liver and kidney were functional. exclusion criteria: * patients who had upper urinary tract disease (e.g., vesico-ureteral reflux or massive stones) that would make multiple transurethral procedures risk; * patients who had urethral strictures that would prevent endoscopic procedures and repeated catheterization; * patients who had prior or concurrent upper urinary tract tumors; * patients who had distant metastases by imaging studies; * patients with uncontrolled infection; underlying disease that was severe or life-threatening; * patients who were lactating; * ecog perform status ≥ 2; * patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment; * patients who are pregnant or nursing; * patients with active tuberculosis (highly positive skin tests allowed if no active disease); * patients with disease that would preclude general anesthesia; * patients with active intractable or uncontrollable infection.
intravesical instillation of hyaluronic acid to decrease incidence of urinary tract infection

Conditions: Urinary Tract Infection

Summary: prospective trial which includes instillation of intravesical hyaluronic acid in an attempt to reduce the incidence of urinary tract infections in patients after orthotopic neobladder reconstruction.


Eligibility criteria:
inclusion criteria: * patients undergoing radical cystectomy and orthotopic neobladder reconstruction exclusion criteria: * patients \<18 years and unwilling to participate in this study

Keywords: orthotopic neobladder urinary tract infection intravesical instillation hyaluronic acid